Cordlife Group Limited (CLIFF)
USD 0.1
(19.52%)
USD 0.1
(19.52%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 2.74 Million SGD | -35.43% |
| 2022 | 4.24 Million USD | 64.15% |
| 2021 | 2.58 Million SGD | 54.7% |
| 2020 | 1.67 Million SGD | 160.94% |
| 2019 | -2.74 Million SGD | 56.18% |
| 2018 | -6.26 Million SGD | -248.07% |
| 2017 | 4.23 Million SGD | 3058.74% |
| 2016 | -143 Thousand SGD | -114.39% |
| 2015 | 994 Thousand SGD | -73.82% |
| 2014 | 3.79 Million SGD | -58.19% |
| 2013 | 9.08 Million SGD | -9.98% |
| 2012 | 10.08 Million SGD | 150.07% |
| 2011 | 4.03 Million SGD | -44.07% |
| 2010 | 7.21 Million SGD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q4 | -1.39 Million USD | -236.72% |
| 2023 Q1 | 261.49 Thousand SGD | 4.6% |
| 2023 FY | 2.74 Million SGD | -35.43% |
| 2023 Q2 | 684 Thousand USD | 161.58% |
| 2023 Q3 | -415.48 Thousand SGD | -160.74% |
| 2022 Q1 | 350.47 Thousand SGD | -85.68% |
| 2022 Q2 | 836 Thousand USD | 138.53% |
| 2022 Q3 | 196.35 Thousand SGD | -76.51% |
| 2022 FY | 4.24 Million USD | 64.15% |
| 2022 Q4 | 250 Thousand USD | 27.32% |
| 2021 Q4 | 2.44 Million SGD | 130.93% |
| 2021 Q3 | 1.06 Million SGD | 135.62% |
| 2021 FY | 2.58 Million SGD | 54.7% |
| 2021 Q1 | 514.82 Thousand SGD | 114.11% |
| 2021 Q2 | -2.97 Million SGD | -678.07% |
| 2020 Q1 | -779.58 Thousand SGD | -125.59% |
| 2020 Q4 | -3.64 Million SGD | -295.63% |
| 2020 FY | 1.67 Million SGD | 160.94% |
| 2020 Q3 | 1.86 Million SGD | 171.91% |
| 2020 Q2 | -2.59 Million SGD | -232.61% |
| 2019 Q1 | 2.98 Million SGD | 320.97% |
| 2019 FY | -2.74 Million SGD | 56.18% |
| 2019 Q4 | 3.04 Million SGD | 61.94% |
| 2019 Q3 | 1.88 Million SGD | 242.62% |
| 2019 Q2 | 549 Thousand SGD | -81.63% |
| 2018 Q3 | 729 Thousand SGD | -26.06% |
| 2018 Q2 | 986 Thousand SGD | -18.44% |
| 2018 Q4 | -1.35 Million SGD | -285.49% |
| 2018 FY | -6.26 Million SGD | -248.07% |
| 2018 Q1 | 1.2 Million SGD | 8.82% |
| 2017 Q2 | 1.12 Million SGD | 386.55% |
| 2017 Q3 | 925 Thousand SGD | -18.07% |
| 2017 FY | 4.23 Million SGD | 3058.74% |
| 2017 Q1 | -394 Thousand SGD | -161.28% |
| 2017 Q4 | 1.11 Million SGD | 20.11% |
| 2016 Q4 | 643 Thousand SGD | -19.52% |
| 2016 Q2 | -931 Thousand SGD | -167.86% |
| 2016 FY | -143 Thousand SGD | -114.39% |
| 2016 Q1 | 1.37 Million SGD | 94.33% |
| 2016 Q3 | 799 Thousand SGD | 185.82% |
| 2015 Q1 | 2.18 Million SGD | 104.87% |
| 2015 Q4 | 706 Thousand SGD | -60.34% |
| 2015 Q3 | 1.78 Million SGD | 54.51% |
| 2015 Q2 | 1.15 Million SGD | -47.3% |
| 2015 FY | 994 Thousand SGD | -73.82% |
| 2014 FY | 3.79 Million SGD | -58.19% |
| 2014 Q4 | 1.06 Million SGD | -37.38% |
| 2014 Q3 | 1.7 Million SGD | 120.34% |
| 2014 Q2 | -8.37 Million SGD | -456.43% |
| 2014 Q1 | 2.35 Million SGD | 10.85% |
| 2013 Q1 | 497 Thousand SGD | -84.81% |
| 2013 FY | 9.08 Million SGD | -9.98% |
| 2013 Q3 | 1.72 Million SGD | -38.72% |
| 2013 Q2 | 2.81 Million SGD | 465.39% |
| 2013 Q4 | 2.12 Million SGD | 23.11% |
| 2012 Q1 | 198 Thousand SGD | -90.91% |
| 2012 FY | 10.08 Million SGD | 150.07% |
| 2012 Q2 | 1.12 Million SGD | 467.68% |
| 2012 Q3 | 2.17 Million SGD | 93.15% |
| 2012 Q4 | 3.27 Million SGD | 50.71% |
| 2011 Q4 | 2.17 Million SGD | 45.1% |
| 2011 Q2 | 1.84 Million SGD | 16.75% |
| 2011 Q1 | 1.58 Million SGD | 0.0% |
| 2011 FY | 4.03 Million SGD | -44.07% |
| 2011 Q3 | 1.5 Million SGD | -18.73% |
| 2010 FY | 7.21 Million SGD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| American Bio Medica Corporation | -1.24 Million USD | 320.853% |
| Arrayit Corporation | -3.62 Million USD | 175.721% |
| Atlantic International Corp. | -5.73 Million USD | 147.85% |
| Biocept, Inc. | -31.98 Million USD | 108.576% |
| Bioqual, Inc. | -19.63 Thousand USD | 14067.817% |
| CardioGenics Holdings Inc | -772.14 Thousand USD | 455.246% |
| DermTech, Inc. | -103.73 Million USD | 102.644% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.48 Billion USD | 99.89% |
| HTG Molecular Diagnostics, Inc. | -20.82 Million USD | 113.169% |
| iMD Companies, Inc. | -175.44 Thousand USD | 1663.444% |
| IDenta Corp. | -1499.00 USD | 183088.659% |
| Interpace Biosciences, Inc. | 2.8 Million USD | 2.175% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | -6989.687% |
| InVitro International | -25.33 Thousand USD | 10925.21% |
| Lumos Diagnostics Holdings Limited | -7.12 Million USD | 138.514% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | 4820.195% |
| Medical Imaging Corp. | -819.48 Thousand USD | 434.724% |
| NovelStem International Corp. | -3.52 Million USD | 177.798% |
| Optigenex Inc. | 1.39 Million USD | -97.22% |
| PharmChem, Inc. | 973.14 Thousand USD | -181.869% |
| Proteome Sciences plc | -1.62 Million USD | 269.217% |
| Response Genetics, Inc | -21.37 Million USD | 112.832% |
| Rennova Health, Inc. | -1.4 Million USD | 294.603% |
| RushNet, Inc. | -684.7 Thousand USD | 500.61% |
| ScreenPro Security Inc. | -2.59 Million USD | 205.808% |
| Stella Diagnostics Inc. | -11.42 Million USD | 124.005% |
| StageZero Life Sciences Ltd. | -7.74 Million USD | 135.408% |
| Todos Medical Ltd. | -9.74 Million USD | 128.139% |